Company
(location)

Company
(location)

Value (M)

Type/product area

Terms/details

Date

APRIL

Bind Therapeutics Inc. (Cambridge, Mass.)

Pfizer Inc. (New York)

ND

Extended terms of the global collaboration to create nanomedicines that optimize the therapeutic potential of two molecularly targeted cancer drugs in Pfizer's pipeline

The collaboration was established in April 2013; the companies agreed to an extension of the timeline for the second program through March 2016; the deal includes about $200M in payments, plus low single- to high single-digit royalties

4/6/15

Coherus Biosciences Inc. (Redwood City, Calif.)

Baxter International Inc. (Deerfield, Ill.)

$12

Amended collaboration to develop and commercialize CHS-0214, a biosimilar of Enbrel (etanercept, Amgen Inc.), for Europe, Canada, Brazil and other markets

Milestones and funding obligations have been revised; expansion includes select pre-commercialization activities; revised milestones may exceed previous funding obligations by about $12M, and Baxter will buy Coherus stock in a private placement

4/16/15

Infinity Pharmaceuticals Inc. (Cambridge, Mass.)

Takeda Pharmaceutical Co. Ltd. (Osaka, Japan)

$52.5

Exercised option to buy out future royalty obligations due to Takeda for sales of duvelisib (IPI-145), Infinity's dual inhibitor of phosphoinositide-3 kinase-delta and P13K-gamma in oncology indications

Infinity paid an exercise fee of $52.5M for the option, purchased in July 2014 from Takeda's Millennium unit for $5M; exercising the option eliminates the future obligation to pay Takeda tiered royalties ranging from 7% to 11% on worldwide net sales of duvelisib in oncology indications

4/1/15

Myriad Genetics Inc. (Salt Lake City)

Astrazeneca plc (London)

ND

Expanded companion diagnostic collaboration for use of Myriad's BRACAnalysis test to prospectively identify which patients with metastatic pancreatic cancer may respond to treatment with Lynparza (olaparib)

Terms were not disclosed

4/2/15

Peptidream Inc. (Tokyo)

Novartis AG (Basel, Switzerland)

ND

Exercised option under a 2012 strategic alliance agreement to obtain a nonexclusive license to Peptidream's Peptide Discovery Platform System technology

Peptidream will receive multistage up-front technology access payments and will be eligible for development milestones and royalties on related product sales

4/3/15

MAY

Pharmaxis Ltd. (Frenchs Forest, Australia)

Boehringer Ingelheim GmbH (Ingelheim, Germany)

$601

Exercised option to in-license PXS4728A from Pharmaxis

Boehringer Ingelheim is paying $31.4M up front and $570M in milestones tied to approval in nonalcoholic steatohepatitis and chronic obstructive pulmonary disease

5/19/15

Selecta Biosciences Inc. (Watertown, Mass.)

Sanofi SA (Paris)

$300

Expanded collaboration in which Sanofi is exercising its option to license Selecta's antigen-specific immunotherapy platform for a program targeting celiac disease

The deal is part of a $900M November 2012 agreement, and Selecta is eligible for up to $300M in milestones and double-digit tiered royalties on net sales

5/14/15


Notes

The date indicated refers to the BioWorld Today issue in which the news item can be found.

For more information about individual companies and/or products, see Thomson Reuters Cortellis.